Close Menu

stock offering

The firm will use the proceeds from the offering for product development efforts and to further its efforts to obtain US Food and Drug Administration clearance of its stool-based DNA colorectal cancer screening product.

The firm will use the proceeds to fund further development of its stool-based DNA colorectal cancer screening product.

The shelf registration is tied to Life Technologies' acquisition late last year of BioTrove.

The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.

Helicos will use the funds for R&D efforts and general corporate purposes. Its shares tumbled in response to the offering.

The firm will apply the proceeds primarily to its drug development efforts.

The firm sold 5.4 million shares at $7 per share.

The firm will offer 4.7 million shares at a price of $7 per share.

Pages

The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.

The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.

Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.

In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.